Joseph G. P. Hnath ([email protected]), Harvard University, Cambridge, Massachusetts. J. Michael McWilliams, Harvard University and Brigham and Women’s Hospital ...
Oncology, ophthalmology, and pegfilgrastim biosimilars reached 81% market share within five years, while others lagged at 26%. CMS increased biosimilar reimbursement to ASP plus 8% of the originator's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results